Matches in SemOpenAlex for { <https://semopenalex.org/work/W2890429391> ?p ?o ?g. }
Showing items 1 to 83 of
83
with 100 items per page.
- W2890429391 abstract "TPS8053 Background: The advent of proteasome inhibitors and immunomodulatory drugs (IMiDs) have significantly improved outcomes in MM, and the first monoclonal antibodies for MM have been recently approved (daratumumab, elotuzumab). Despite novel therapies and improved disease management, MM is still considered incurable and most pts relapse, confirming the need for additional treatment options. MM cells express PD-L1, with higher levels observed after relapse and with advanced disease. Additionally, PD-L1–expressing immune cells in the microenvironment promote MM cell survival and potential immune escape. However, anti–PD-1 monotherapy did not result in objective responses in the MM cohort of a Ph I study, suggesting that MM pts need combination therapy. Daratumumab has activity as a single agent, as well as in combination with IMiDs plus dexamethasone and bortezomib plus dexamethasone in R/R MM. Immunomodulatory activity for daratumumab has also been reported. Thus, disruption of the PD-L1/PD-1 pathway may be additive or synergistic. The safety and efficacy of atezo (anti–PD-L1) alone or with lenalidomide or pomalidomide and/or daratumumab will be evaluated in a Ph Ib study of MM pts. NCT02431208. Methods: R/R MM pts with ≤ 3 prior therapies will be enrolled in Cohorts A (atezo), B (atezo + lenalidomide), D (atezo + daratumumab) and E (atezo + daratumumab + lenalidomide); MM pts with measurable disease after ASCT (Cohort C: atezo) or ≥ 3 prior therapies (Cohort F: atezo + daratumumab + pomalidomide) will also be enrolled. Cohorts B, D, E and F include a safety run-in (D) or dose escalation phase (B, E, F) and an expansion. Lenalidomide and pomalidomide will be dose escalated and the MTD evaluated in expansion phases. Atezo will be given at 1200 mg IV (A, B, C) or 840 mg IV (D, E, F); pts will get daratumumab at 16 mg/kg IV (D, E, F). All pts will be ECOG PS ≤ 2. Primary endpoints are ORR and the RP2D of lenalidomide and pomalidomide with atezo and daratumumab and the RP2D of lenalidomide with atezo. DOR and PFS are secondary endpoints; safety, PK and the relationship between biomarkers and other endpoints, including efficacy, will be assessed. Pts will be enrolled at 19 US sites. Clinical trial information: NCT02431208." @default.
- W2890429391 created "2018-09-27" @default.
- W2890429391 creator A5006038485 @default.
- W2890429391 creator A5007237464 @default.
- W2890429391 creator A5012659772 @default.
- W2890429391 creator A5026151069 @default.
- W2890429391 creator A5034791164 @default.
- W2890429391 creator A5049554397 @default.
- W2890429391 creator A5069676334 @default.
- W2890429391 creator A5077169512 @default.
- W2890429391 creator A5088696429 @default.
- W2890429391 date "2017-05-20" @default.
- W2890429391 modified "2023-09-22" @default.
- W2890429391 title "A phase Ib study of atezolizumab (atezo) alone or in combination with lenalidomide or pomalidomide and/or daratumumab in patients (pts) with multiple myeloma (MM)." @default.
- W2890429391 doi "https://doi.org/10.1200/jco.2017.35.15_suppl.tps8053" @default.
- W2890429391 hasPublicationYear "2017" @default.
- W2890429391 type Work @default.
- W2890429391 sameAs 2890429391 @default.
- W2890429391 citedByCount "3" @default.
- W2890429391 countsByYear W28904293912018 @default.
- W2890429391 countsByYear W28904293912020 @default.
- W2890429391 countsByYear W28904293912021 @default.
- W2890429391 crossrefType "journal-article" @default.
- W2890429391 hasAuthorship W2890429391A5006038485 @default.
- W2890429391 hasAuthorship W2890429391A5007237464 @default.
- W2890429391 hasAuthorship W2890429391A5012659772 @default.
- W2890429391 hasAuthorship W2890429391A5026151069 @default.
- W2890429391 hasAuthorship W2890429391A5034791164 @default.
- W2890429391 hasAuthorship W2890429391A5049554397 @default.
- W2890429391 hasAuthorship W2890429391A5069676334 @default.
- W2890429391 hasAuthorship W2890429391A5077169512 @default.
- W2890429391 hasAuthorship W2890429391A5088696429 @default.
- W2890429391 hasConcept C121608353 @default.
- W2890429391 hasConcept C126322002 @default.
- W2890429391 hasConcept C143998085 @default.
- W2890429391 hasConcept C2775949291 @default.
- W2890429391 hasConcept C2776063141 @default.
- W2890429391 hasConcept C2776364478 @default.
- W2890429391 hasConcept C2777701055 @default.
- W2890429391 hasConcept C2778524551 @default.
- W2890429391 hasConcept C2779609412 @default.
- W2890429391 hasConcept C2780030458 @default.
- W2890429391 hasConcept C2781119759 @default.
- W2890429391 hasConcept C71924100 @default.
- W2890429391 hasConceptScore W2890429391C121608353 @default.
- W2890429391 hasConceptScore W2890429391C126322002 @default.
- W2890429391 hasConceptScore W2890429391C143998085 @default.
- W2890429391 hasConceptScore W2890429391C2775949291 @default.
- W2890429391 hasConceptScore W2890429391C2776063141 @default.
- W2890429391 hasConceptScore W2890429391C2776364478 @default.
- W2890429391 hasConceptScore W2890429391C2777701055 @default.
- W2890429391 hasConceptScore W2890429391C2778524551 @default.
- W2890429391 hasConceptScore W2890429391C2779609412 @default.
- W2890429391 hasConceptScore W2890429391C2780030458 @default.
- W2890429391 hasConceptScore W2890429391C2781119759 @default.
- W2890429391 hasConceptScore W2890429391C71924100 @default.
- W2890429391 hasLocation W28904293911 @default.
- W2890429391 hasOpenAccess W2890429391 @default.
- W2890429391 hasPrimaryLocation W28904293911 @default.
- W2890429391 hasRelatedWork W2025229648 @default.
- W2890429391 hasRelatedWork W2253136404 @default.
- W2890429391 hasRelatedWork W2595842703 @default.
- W2890429391 hasRelatedWork W2597908369 @default.
- W2890429391 hasRelatedWork W2599271846 @default.
- W2890429391 hasRelatedWork W2602101168 @default.
- W2890429391 hasRelatedWork W2605568273 @default.
- W2890429391 hasRelatedWork W2739338574 @default.
- W2890429391 hasRelatedWork W2781388087 @default.
- W2890429391 hasRelatedWork W2888379970 @default.
- W2890429391 hasRelatedWork W2890779740 @default.
- W2890429391 hasRelatedWork W2891356385 @default.
- W2890429391 hasRelatedWork W2952813810 @default.
- W2890429391 hasRelatedWork W2980849131 @default.
- W2890429391 hasRelatedWork W3113327340 @default.
- W2890429391 hasRelatedWork W3132592784 @default.
- W2890429391 hasRelatedWork W3168519332 @default.
- W2890429391 hasRelatedWork W3171552343 @default.
- W2890429391 hasRelatedWork W3214404575 @default.
- W2890429391 hasRelatedWork W617154716 @default.
- W2890429391 isParatext "false" @default.
- W2890429391 isRetracted "false" @default.
- W2890429391 magId "2890429391" @default.
- W2890429391 workType "article" @default.